IL6ST and rheumatoid arthritis: In analyzing data that represented patient’s week 16 clinical outcomes, we discovered that sgp130, logIL-6, logIP-10 and logsTNFR-II were significant markers to predict if naïve RA patients would experience remission or not post tocilizumab therapy.